NON-TRADITIONALENDPOINTSINLUNGCANCER-Patient.ppt

NON-TRADITIONAL ENDPOINTS IN LUNG CANCER- Patient Reported Outcomes -;ENDPOINTS IN DECISION-MAKING- Clinical Trials and Patient Management -;NON-SMALL CELL LUNG CANCER- Quality of Life at Baseline: Influence on Survival -- Prospective Analysis of 673 Patients at 30 Centers -;NON-SMALL CELL LUNG CANCER- Survival: Supportive Care and Chemotherapy 1991- 2001 (N = 10,995 / 9361) -;PATIENT REPORTED OUTCOMES (“PROs”)- Rationale and Need -;SYMPTOMS OF LUNG CANCER- By Patient Reports (N = 121) -;NON-SMALL CELL LUNG CANCER - Number of Presenting Symptoms at Baseline -; ;QUALITY OF LIFE INSTRUMENTS- Dimensions -;- Conceptual Model for Clinical Trials: THE “LCSS” -;QUALITY OF LIFE - Questions -;QUALITY OF LIFE INSTRUMENTS- Instrument Focus -;QUALITY OF LIFE INSTRUMENTS- Lung Cancer Specific -;LUNG CANCER SPECIFIC INSTRUMENTS- Psychometrics (1) -;QUALITY OF LIFE INSTRUMENTS- Good reliability features include: -;QOL MEASURES FOR LUNG CANCER - Example: Reliability Coefficients -;LUNG CANCER SPECIFIC INSTRUMENTS- Psychometrics (2) -;QUALITY OF LIFE INSTRUMENTS - Additional Information -;PATIENT RESPONSE OUTCOMEINSTRUMENTS IN LUNG CANCER TRIALS- Other Questionnaires -;NON-SMALL CELL LUNG CANCER - Clinical Benefit and Quality of Life –;RANDOMIZED PHASE II TRIAL OF IRESSA AT 2 DOSE LEVELS – “IDEAL 2”Quality of Life / Clinical Benefit: ASCO 2002 Abstract #1167; ;NON-SMALL CELL LUNG CANCER - Clinical Benefit and Quality of Life –; ;PROSPECTIVE CLINICAL TRIAL IN NSCLC- Causes of Patient Attrition -; ;NON-SMALL CELL LUNG CANCER- Quality of Life at Baseline: Influence on Survival -- Prospective Analysis of 673 Patients at 30 Centers -;QUALITY OF LIFE- Baseline Values for Age and LCSS -;QUALITY OF LIFE IN LUNG CANCER- Evaluation Problems in Advanced Disease –; ; ; ;; ; ;QUALITY OF LIFE INSTRUMENTS- Step #2: Compare Feasibility -;QUALITY OF LIFE INSTRUMENT